Definium Therapeutics' stock plummeted 5.34% during intraday trading on Friday.
The decline follows Piper Sandler analyst David Amsellem lowering the firm's price target on Definium Therapeutics to $48 from $49 while maintaining an Overweight rating. Analysts have also been providing new insights on the healthcare company, contributing to market sentiment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments